Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Fresenius Medical Care North America (FMCNA), the North American division of Fresenius Medical Care (FMS - Snapshot Report), recently revealed that it provides dialysis at night for patients who are asleep. The company’s quality of care at night matches its day time care at clinics.

The company has set up over 140 night time center-based dialysis programs in the U.S. It plans to open more nocturnal centers during 2013.

Dialysis at night, while patients are sleeping, is gaining popularity. While such dialysis treatment takes a longer period of time, patients accrue benefit as nocturnal treatment leaves them free for work or other business during the day. Since treatment at night spans a longer time, waste material is gradually removed from the patient, which yields a more gentle therapy for most recipients.

Dialysis sustains life by removing surplus fluids and cleansing waste material from the blood stream when a patient’s kidneys stop functioning.

Fresenius is the largest provider of products and services for patients undergoing dialysis treatment on the planet. The company’s principal competitor in the U.S. is DaVita Inc. (DVA - Analyst Report), which provides dialysis services for patients suffering from chronic kidney failure or end stage renal disease. Fresenius also competes with Baxter International (BAX - Analyst Report) in certain niches such as the peritoneal dialysis products.

The company continues to register strong operating results in the North American as well as overseas markets. The integration of recent acquisitions is also expected to be accretive to Fresenius’ earnings in the near term. However, the contagion of economic problems remains a matter of concern.

The stock carries a Zacks #3 Rank, which translates into a short-term Hold rating.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%